Citadel Advisors
HSTO

Citadel Advisors’s Histogen Inc. Common Stock HSTO Stock Holding History

Citadel Advisors’s Portfolio HSTO Stock Details HSTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-199
Closed -$13K – 10016
2019
Q3 		$13K Sell
199
-48
-19% -$3.13K ﹤0.01% 9019
2019
Q2 		$13K Sell
247
-138
-36% -$23.9K ﹤0.01% 9008
2019
Q1 		$83K Buy
385
+134
+53% +$54K ﹤0.01% 8618
2018
Q4 		$87K Buy
251
+149
+146% +$116K ﹤0.01% 8308
2018
Q3 		$118K Buy
102
+32
+46% +$29.5K ﹤0.01% 8507
2018
Q2 		$60K Buy
+70
New +$58.1K ﹤0.01% 8404
2016
Q3 		– Sell
-71
Closed -$29K – 7959
2016
Q2 		$29K Buy
+71
New +$34.8K ﹤0.01% 6531

Other funds holding HSTO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's HSTO Position: Q3 2022 in Review

Citadel Advisors sold out of Histogen Inc. Common Stock (HSTO) in Q3 2022, closing a stake of 10,551 shares — an estimated $24K sold.

Citadel Advisors first reported a position in HSTO in Q2 2015 and held it in 23 quarters. The position peaked at $1.69M in Q3 2015. 13 funds tracked by Wall St. Rank hold HSTO as of Q3 2022.

  • Citadel Advisors reported no remaining Histogen Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 10,551 Histogen Inc. Common Stock shares in Q3 2022, an estimated $24K.
  • Citadel Advisors first reported a position in Histogen Inc. Common Stock in Q2 2015 and held it in 23 quarters.
  • Citadel Advisors's Histogen Inc. Common Stock position peaked at $1.69M in Q3 2015.
  • 13 funds tracked by Wall St. Rank held Histogen Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.